Impact of Cross-border Mergers and Acquisitions on the Development of Chinese Pharmaceutical Exports and Imports
Abstract
The article is devoted to the research into the impact of cross-border mergers and acquisitions, conducted by international pharmaceutical companies in China, on Chinese participation in international pharmaceutical trade. Relevance of the study resides in the importance of mergers and acquisitions as instruments that are widely used in a foreign markets penetration process and that lead to the enhancement of intercorporate trade, thus significantly influencing country’s foreign trade. International pharmaceutical companies expanded their operations in Chinese market during the last two decades as a result of the market liberalization. Mergers and acquisitions, conducted by international players, have directly or indirectly led to higher growth rates of Chinese foreign trade in pharmaceutical products, to geographic diversification of pharmaceutical exports and to an increase in deliveries from developed countries. China more than doubled its share in global exports of pharmaceutical products and almost quadrupled its share as an importer of pharmaceuticals. The specific features of Chinese pharmaceutical trade are high growth rates in imports and imports’ significant excess over exports. Substantial proportion of Chinese imports is constituent by pharmaceutical components, that are needed to ensure production of high quality pharmaceuticals in China. Mergers and acquisitions play important role in this process and cause changes in geographical structure of imports. Seven biggest suppling countries, which hold more than two thirds of imports to China, represent the countries of origin of companies that are actively involved into mergers and acquisitions in Chinese pharmaceutical market. The research results can be used by public regulatory authorities for the elaboration of industrial development policies through stimulating or deterring foreign direct investments. Research can be of use to pharmaceutical companies in formulating competition strategies for domestic and foreign markets.
About the Authors
O. A. Klochko
Associate Professor National Research University Higher School of Economics
Russian Federation
Russian Federation
PhD in Economics
101000, Myasnitskaya St., 20, Moscow
A. V. Chugunova
National Research University Higher School of Economics
Russian Federation
Russian Federation
Assistant
101000, Myasnitskaya St., 20, Moscow
References
1. Balandina G.V., Spartak A.N. (2017) Prospects and Limitations of Russia’s Par-ticipation in Regional and Global Val-ue Chains]. Rossijskij vneshneekonomi-cheskij vestnik, no 11, pp. 3–16. Available at: https://cyberleninka.ru/article/n/pers-pektivy-i-ogranicheniya-uchastiya-rossii-v-regionalnyh-i- globalnyh-tsepochkah-stoimosti/viewer, accessed 12.12.2019 (in Russian).
2. Bayer Completes Acquisition of Di-hon Pharmaceutical Group Co., Ltd. in China (2014). Investor.bayer.de. Avail-able at: https://www.investor.bayer.de/se-curedl/12180, accessed 06.02.2019
3. Campbell D., Chui M. (2010) Phar-merging Shake-up: New Imperatives in a Redefined World. IMS Health. Available at: http://ficci.in/spdocument/20174/PHAR-MERGING%20SHAKE-UP.pdf, accessed 12.12.2019.
4. Chinese Pharmaceutical Market: Battle withtheDeficit](2018).Diapazon-pharm.ru, September 10, 2018. Available at: https://www.diapazon-pharm.ru/kitai skii-farmacevticeskii-rynok-borba-s-defici tom, accessed 12.12.2019 (in Russian).
5. Euromonitor International Passport Database (2018). Euromonitor. Available at: https://www.portal.euromonitor.com, accessed 12.12.2019.
6. Ge Sh., Luo W. (2015) Multinational Enterprises Entry and Industrial Structure of Manufacturing Sector in China: Based on Global Value Chains Perspective. Jingji yanjiu, no 11, pp. 34–48 (in Chinese).
7. Graham M. (2005) Bausch & Lomb Completes Acquisition of Shandong Chia Tai Freda Pharmaceutical Group. Busi-ness Wire, September 26, 2005. Avail-able at: https://www.businesswire.com/ news/home/20050926005560/en/Bausch-Lomb-Completes- Acquisition-Shandong-Chia-Tai, accessed 12.12.2019.
8. GSK to Purchase Shenzhen Neptu-nus Stake in Previously Formed Joint Venture for Influenza Vaccines in China (2011). GSK, June 14, 2011. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-to-purchase-shenzhen-nep-tunus-stake-in-previously-formed-joint-venture- for-influenza-vaccines-in-china/, accessed 16.12.2019.
9. Kondrat’ev V.B. (2014) Global Value ChainsinModernEconomy.Perspektivy.info. Available at: http://www.perspektivy.info/ print.php?ID=269044, accessed 12.12.2019 (in Russian).
10. Li X., Zheng Y., Wang C.L. (2016) In-ter-firm Collaboration in New Prod-uct Development in Chinese Pharmaceu-tical Companies. Asia Pacific Journal of Management, vol. 33, no 1, pp. 165–193. DOI: 10.1007/s10490-015-9451-y
11. Liu Ju (2016) Discussion on the Re-gional Economic Integration in Asia-Pacif-ic Area with the Perspective of GVCs. Guoji jingju hezuo, no 11, pp. 42–46 (in Chinese).
12. Mamuto А.O. (2012) The Use of In-ternational Experience in Russia’s Phar-maceutical Industry. Ekonomika i uprav-lenie, no 9(83), pp. 73–77. Available at: https://elibrary.ru/download/elibrary_17976401_13454873.pdf,accessed 12.12.2019(in Russian).
13. Market Intelligence (2018). S&P Capi-tal IQ. Available at: https://www.capitaliq. com, accessed 12.12.2019.
14. Pan W., Lou I., Li H. (2015) On-chain Trade and Business Cycle Co-movement: Regulatory and Chinese Experience. Jingji yanjiu, no 11, pp. 20–33 (in Chinese).
15. RodwinV.G.,FabreG.,AyoubR.F.(2018) BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Manage-ment. International Journal of Health Poli-cy Management, vol. 7, no 3, pp. 201–206. DOI: 10.15171/ijhpm.2017.145
16. Romashkina V.А. (2017) The Impact of Direct Foreign Investment on the De-velopment of Economy in China. Vestnik of the Russian Plekhanov University of Eco-nomics, no 1(97), pp. 189–198 (in Russian). DOI: 10.21686/2413-2829-2018-1-189-198
17. Sulton S. (2011) Novartis Acquires Chi-nese Vaccine Company. PharmTech, March 24, 2011. Available at: http://www.pharm-tech.com/novartis-acquires-chinese-vac-cine-company-0, accessed 12.12.2019.
18. The Next Phase: Opportunities in Chi-na’s Pharmaceuticals Market (2011). De-loitte. Available at: https://www2.deloitte. com/content/dam/Deloitte/ch/Docu-ments/life-sciences-health-care/ch_Stud-ie_Pharmaceutical_China_05052014.pdf, accessed 12.12.2019.
19. Trade in Value Added (2018). OECD. Available at: http://www.oecd.org/sdd/ measuring-trade-in-value-added.htm, ac-cessed 12.12.2019.
20. Trade Statistics for International Busi-ness Development (2018). TradeMap. Available at: https://www.trademap.org, accessed 12.12.2019.
21. Tremblay J.-F. (2010) Big Pharma Set-tles in China. Chemical and Engineer-ing News, November 8, 2010. Available at: http://pubs . acs . org/cen/news/88/ i 4 5 / 8 8 4 5 n o t w 1 . h t m l ? u t m _ s o u r c e = f e e d b u r n e r & u t m _ m e d i um=feed&utm _ campaign=Feed% 3 A + c e n _ l at e s t n e w s + % 2 8 C h e m i cal+%26+Engineering+News%3A+La test+News%29, accessed 12.12.2019.
22. World Health Statistics 2017 (2017). World Health Organization. Avail-able at: http://www.who.int/iris/hand le/10665/255336, accessed 12.12.2019.
23. World Investment Report 2018 (2018). Annex Table 10. Value of Cross-Bor-der M&A Purchases, by Sector/Indus-try, 1990-2017. UNCTAD. Available at: https://unctad.org/en/Pages/DIAE/ World%20Investment%20Report/Annex-Tables.aspx, accessed 12.12.2019.
24. Zhang F., Zhou J. (2017) What’s Next for Pharma Innovation in China. McKin-sey & Company, September, 2017. Avail-able at: https://www.mckinsey.com/in-dustries/pharmaceuticals-and-medical-products/our-insights/whats-next-for-pharma-innovation-in-china, accessed 12.12.2019.
Review
For citations:
Klochko O.A., Chugunova A.V. Impact of Cross-border Mergers and Acquisitions on the Development of Chinese Pharmaceutical Exports and Imports. Global Infrastructure in the Digital Age. 2019;12(6):170-187. (In Russ.)
Views:
3570
Email this article 